Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis

Drug Design, Development and Therapy
Yan TieMing Liu

Abstract

Immune checkpoint inhibitors have developed rapidly and have demonstrated antitumor activity in various cancers. To evaluate the safety and efficacy of atezolizumab in treating cancers, we conducted this meta-analysis. Embase, PubMed, MEDLINE, the Central Register of Controlled Trials of the Cochrane Library, and the American Society of Clinical Oncology database were searched for relevant studies. The primary outcomes were any grade adverse events (AEs) and grade ≥3 AEs. The secondary outcomes were overall objective response rate, pooled 6-month progression-free survival (PFS) rate, 1-year overall survival (OS) rate, median PFS, and median OS. Our meta-analysis was based on 14 clinical trials with 3,266 patients. The total risk of any grade AEs reached 69%, while grade ≥3 AEs happened in only 13% of participants. The overall atezolizumab-related death rate was 0.17%. Major common AEs involved fatigue (24.5%), decreased appetite (13.2%), nausea (12.3%), diarrhea (10.8%), pyrexia (10.7%), pruritus (9.6%), cough (9.5%), edema peripheral (8.6%), and rash (8.4%). The most common severe AEs were fatigue (2.2%), anemia (1.9%), and dyspnea (1.9%). Meanwhile, we found that 6% patients reached complete response and 16% partial response....Continue Reading

Citations

Oct 14, 2020·Journal of Investigative Medicine High Impact Case Reports·Asim KichlooAsma Taj
Nov 25, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikJohanna Bendell
May 28, 2021·Biochemical Pharmacology·Liqian MaErik R Nelson
Jul 18, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Saikat GhoshSubhas Bhowmick

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

Review Manager
Comprehensive Meta - Analysis
STATA

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.